BusinessPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaBy Nasdaq OMXSep 7, 2017, 12:10 PM UTC
BusinessPreclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXOct 24, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXOct 10, 2016, 12:05 PM UTC
BusinessVaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung CancerBy Nasdaq OMXOct 6, 2016, 1:45 PM UTC
BusinessNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple CancersBy Nasdaq OMXSep 6, 2016, 12:45 PM UTC
BusinessPeregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016By Nasdaq OMXSep 1, 2016, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent DevelopmentsBy Nasdaq OMXMar 9, 2016, 1:00 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXMar 7, 2016, 9:05 PM UTC
